H U Scherer1, G-R Burmester. Show Affiliations » 1. Klinik für Rheumatologie und klinische Immunologie, Charité-Universitätsmedizin Berlin. ulrich.scherer@charite.de
Abstract
Entities: Disease
Mesh： See more » AbataceptAdalimumabAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntirheumatic Agents/administration & dosageAntirheumatic Agents/therapeutic useArthritis, Juvenile/drug therapyArthritis, Psoriatic/drug therapyArthritis, Rheumatoid/diagnosisChildClinical Trials, Phase II as TopicCohort StudiesCollagen Diseases/drug therapyDrug Therapy, CombinationEtanerceptGlucocorticoids/administration & dosageGlucocorticoids/therapeutic useGranulomatosis with Polyangiitis/drug therapyHumansImmunoconjugates/administration & dosageImmunoconjugates/therapeutic useImmunoglobulin G/administration & dosageImmunoglobulin G/therapeutic useInfliximabMethotrexate/administration & dosageMethotrexate/therapeutic usePlacebosPolymyalgia Rheumatica/drug therapyRandomized Controlled Trials as TopicReceptors, Tumor Necrosis Factor/administration & dosageReceptors, Tumor Necrosis Factor/therapeutic useRemission InductionRheumatic Diseases/drug therapyRituximabSpondylarthropathies/drug therapySpondylitis, Ankylosing/drug therapySulfasalazine/administration & dosageSulfasalazine/therapeutic useTime FactorsTumor Necrosis Factor-alpha/antagonists & inhibitors
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntirheumatic AgentsGlucocorticoidsImmunoconjugatesImmunoglobulin GPlacebosReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alphaSulfasalazineRituximabAbataceptInfliximabAdalimumabtocilizumabEtanerceptMethotrexate
Year: 2006 PMID： 17036270 DOI： 10.1055/s-2006-951364
Source DB: PubMed Journal: Dtsch Med Wochenschr ISSN： 0012-0472 Impact factor: 0.628